Measurement of utility values in the UK for health states related to immune thrombocytopenic purpura

References

• George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996 Jul 1;88:3-40
   PubMed Web of Science ®Google Scholar
• McMillan R, Wang L, Tomer A, et al. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 2004;103:1364-9
   PubMed Web of Science ®Google Scholar
• Macarthur D. Orphan drugs in Europe: pricing, reimbursement, funding and market access issues. Justpharmareports. 2008 [cited 2008; Available from: www.justpharmareports.com
   Google Scholar
• Aledort LM, Lyons RM, Okano G, et al. The clinical and direct medical cost burden of splenectomy among managed care patients with chronic immune thrombocytopenic purpura (ITP). Abstract at the American Society of Hematology (ASH) Annual Meeting, 2006
   Google Scholar
• McMillan R, Bussel JB, George JN, et al. Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol 2008;83:150-4
   PubMed Web of Science ®Google Scholar
• Snyder CF, Mathias SD, Cella D, et al. Health-related quality of life of immune thrombocytopenic purpura patients: results from a web-based survey. Curr Med Res Opin 2008;24:2767-76
   PubMed Web of Science ®Google Scholar
• Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115:168-86
   PubMed Web of Science ®Google Scholar
• Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006;355:1672-81
   PubMed Web of Science ®Google Scholar
• EuroQol – a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990;16:199-208
   Google Scholar
• Amgen. A randomized, placebo controlled study evaluating the efficacy and safety of AMG 531 treatment of thrombocytopenic subjects with immune (idiopathic) thrombocytopenic purpura (ITP) prior to splenectomy (Protocol 20030212 Study Report): Data on file, Amgen; 2006 [NCT00102323]
   Google Scholar
• Amgen. A randomized, placebo controlled study evaluating the efficacy and safety of AMG 531 treatment of thrombocytopenic subjects with immune (idiopathic) thrombocytopenic purpura (ITP) refractory to splenectomy (Protocol 20030105 Study Report): Data on file, Amgen; 2006 [NCT00102336]
   Google Scholar
• Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008;371:395-403
   PubMed Web of Science ®Google Scholar
• Mathias SD, Bussel JB, George JN, et al. A disease-specific measure of health-related quality of life in adults with chronic immune thrombocytopenic purpura: psychometric testing in an open-label clinical trial. Clin Ther 2007;29:950-62
   PubMed Web of Science ®Google Scholar
• Mathias SD, Gao SK, Rutstein M, et al. Evaluating clinically meaningful change on the ITP-PAQ: preliminary estimates of minimal important differences. Curr Med Res Opin 2009;25:375-83
   PubMed Web of Science ®Google Scholar
• Mathias SD, Bussel JB, George JN, et al. A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: its development and validation. Health Qual Life Outcomes 2007;5:11
   PubMed Web of Science ®Google Scholar
• Furlong W, Feeny D, Torrance GW, et al. Guide to design and development of health-state utility instrumentation. Hamilton, Ontario: McMaster University, 1990
   Google Scholar
• Torrance GW. Utility approach to measuring health-related quality of life. J Chronic Dis 1987;40:593-603
   PubMedGoogle Scholar
• MVH Group. The measurement and valuation of health. Final report on the modelling of valuation tariffs York, UK: York Centre for Health Economics, 1995
   Google Scholar
• Tufts Medical Center. The Center for the Evaluation of Value and Risk in Health. Cost-Effectiveness Analysis (CEA) Registry. [cited; Available from: https://research.tufts-nemc.org/cear/Default.aspx (Last updated through September 2009)
   Google Scholar
• Xie F, Blackhouse G, Assasi N, et al. Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in Canadian adults with chronic immune thrombocytopenic purpura. Clin Ther 2009;31:1082-91; discussion 1066-8
   PubMed Web of Science ®Google Scholar
• Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-108
   PubMed Web of Science ®Google Scholar
• Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002;21:271-92
   PubMed Web of Science ®Google Scholar
• Brazier JE, Ratcliffe J, Tsuchiya A, et al. Measuring and valuing health for economic evaluation, Oxford: Oxford University Press, 2007
   Google Scholar